265005

Dexamethasone

≥99% (TLC), solid, NOS induction inhibitor, Calbiochem

• Synonym(s): Dexamethasone, 9α-Fluoro-16α-methylprednisolone
• Empirical Formula (Hill Notation): C₂₂H₂₉FO₅
• CAS Number: 50-02-2
• Molecular Weight: 392.46
• MDL number: MFCD00064136
• UNSPSC Code: 51422306
• NACRES: NA.77

Properties

• Product Name: Dexamethasone, Most active and highly stable glucocorticoid.
• description: Merck USA index - 14, 2943
• Quality Level: 100
• Assay: ≥99% (TLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze
• color: white
• solubility: DMSO: 25 mg/mL; chloroform: soluble; ethanol: soluble
• shipped in: ambient
• storage temp.: 2-8°C
• SMILES string: F[C@@]21[C@H]([C@H]4[C@@]([C@@]([C@@H](C4)C)(O)C(=O)CO)(C[C@@H]2O)C)CCC3=CC(=O)C=C[C@@]31C
• InChI: 1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
• InChI key: UREBDLICKHMUKA-CXSFZGCWSA-N

Description

General description

Most active and highly stable glucocorticoid. Causes a reduction in cyclin A and Cdk2 activity, and inhibition of G₁/S transition in osteoblasts. Inhibits the phosphorylation of retinoblastoma (Rb) protein. Inhibits the expression of inducible but not constitutive nitric oxide synthase in vascular endothelial cells (IC₅₀ = 5 nM). Enhances active cation transport in aortic smooth muscle cells by stimulating the Na⁺ - K⁺ pump. Induces apoptosis in human thymocytes.

Biochem/physiol Actions

Cell permeable: no

Primary Target
Phosphorylation of rb protein

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 5 nM Inhibiting the expression of inducible but not constitutive nitric oxide synthase in vascular endothelial cells

Warning

Toxicity: Carcinogenic / Teratogenic (D)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.

Other Notes

Reil, T.D., et al. 2000. J. Surg. Res.92, 108.
Smith, E., et al. 2000. J.Biol. Chem. 275, 1992.
Petit, P.X., et al. 1995. J. Cell Biol.130, 157.
Stern, N., et al. 1994. Am. J. Hypertens. 7, 146.
Donis, J.A., et al. 1993. Biotechniques15, 786.
Ohoka, Y., et al. 1993. Biochem. Biophys. Res. Commun.197, 916.
Sarin, A., et al. 1993. J. Exp. Med.178, 1693.
Vandewalle, A., et al. 1993. J. Cell Physiol.156, 383.
Nieto, M.A., et al. 1992. Clin. Exp. Immunol.88, 341.
Walsh, D., and Avashia, J. 1992. Cleveland Clin. J. Med. 59, 505.
Warters, R.L. 1992. Cancer Res.52, 883.
Sperber, K., et al. 1991. J. Allergy Clin. Immunol.87, 490.
Radomski, M.W., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 10043.
Bettger, W.J., et al. 1981. Proc. Natl. Acad. Sci. USA78, 5588.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Pictograms: GHS08
• Signal Word: Danger
• Hazard Statements: H360FD
• Precautionary Statements: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Hazard Classifications: Repr. 1B
• Storage Class Code: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable